Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Von Willebrand's Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Von Willebrand's Disease - Pipeline Insight, 2024," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Von Willebrand's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Von Willebrand's Disease pipeline landscape is provided which includes the disease overview and Von Willebrand's Disease treatment guidelines.
The assessment part of the report embraces, in depth Von Willebrand's Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Von Willebrand's Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Von Willebrand's Disease R&D. The therapies under development are focused on novel approaches to treat/improve Von Willebrand's Disease.
Von Willebrand's Disease Emerging Drugs Chapters
This segment of the Von Willebrand's Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Von Willebrand's Disease Emerging Drugs
BT200: Band TherapeuticsBT 200 is a pegylated synthetic RNA oligonucleotide is being developed by Band Therapeutics for the prevention of arterial thrombosis and treatment of Von Willebrand's Disease. The drug is currently in phase II stage of clinical trial evaluation for the treatment of Von Willebrand's Disease.
Von Willebrand's Disease: Therapeutic Assessment
This segment of the report provides insights about the different Von Willebrand's Disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Von Willebrand's Disease
There are approx. 4+ key companies which are developing the therapies for Von Willebrand's Disease. The companies which have their Von Willebrand's Disease drug candidates in the most advanced stage, i.e. phase II include, Band Therapeutics.
Key Questions
- How many companies are developing Von Willebrand's Disease drugs?
- How many Von Willebrand's Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Von Willebrand's Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Von Willebrand's Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Von Willebrand's Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Band Therapeutics
- TagCyx Biotechnologies
- China Biologic Products
- Thrombotargets Corporation
- Sanofi
Key Products
- BT200
- TAGX 0004
- Human von Willebrand Factor
- TT 173
- BIVV001
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Von Willebrand's Disease Report Insights
- Von Willebrand's Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Von Willebrand's Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
- Band Therapeutics
- TagCyx Biotechnologies
- China Biologic Products
- Thrombotargets Corporation
- Sanofi
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/zhzida
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
